KAKaty Lísias Gondim Dias de Albuquerque

Katy Lísias Gondim Dias de Albuquerque

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Katy Lísias Gondim Dias de Albuquerque has a total of 34 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Effects of Cannabidiol‐Rich Cannabis Oil on Facial Expression Recognition and Theory of Mind in Children With Autism Spectrum Disorder: A Randomized Clinical Trial

    by Wandersonia Moreira Brito Medeiros, Estácio Amaro da Silva Junior, Katy Lísias Gondim Dias de Albuquerque, Marine Diniz da Rosa, Amanda Gleiciane de Lima Oliveira, Maycon Jônatas da Silva, João Vitor Andrade Fernandes, Emily Caroline Costa Vieira, João Paulo Mendes dos Santos, Thais Cavalcanti Borges, et al.

    To evaluate, in a post hoc subanalysis, the effects of cannabidiol (CBD)‐rich cannabis oil on facial expression recognition and theory of mind in children with autism spectrum disorder (ASD). This post hoc subanalysis included children from a double‐blind, randomized, placebo‐controlled trial who completed social cognition assessments at baseline and after treatment. Participants received CBD‐rich cannabis oil or placebo for 12 weeks. Facial expression recognition and theory of mind were assessed using neuropsychological tasks. Between‐group differences were evaluated using the Mann–Whitney U test, whereas within‐group changes were assessed using the Wilcoxon signed‐rank test. Nineteen Brazilian children with ASD were included (72.7% male; mean age, 7.82 years). Within‐group analyses showed significant improvements in facial expression recognition ( p = 0.030) and verbal theory of mind ( p = 0.016) after treatment in the CBD group, whereas corresponding changes in the placebo group were not statistically significant. However, between‐group comparisons showed no significant differences after treatment in facial expression recognition ( p = 0.527) or verbal theory of mind ( p = 0.901). Total theory of mind scores improved significantly within both groups, with no significant between‐group difference ( p = 0.967). Although significant within‐group improvements in facial expression recognition and verbal theory of mind were observed following CBD‐rich cannabis oil treatment, these changes were not significantly different from those observed with placebo. Given the small sample size and exploratory post hoc design, these findings should be interpreted cautiously and do not establish a treatment effect of CBD on social cognition in children with ASD. Trial Registration: Brazilian Clinical Trials Registry (ReBEC), RBR‐5wr2cqq (UTN: U1111‐1261‐4178), accessible at https://ensaiosclinicos.gov.br/rg/RBR‐5wr2cqq


  • Open Access

    Acompanhamento clínico de cinco crianças com transtorno do espectro autista que usam óleo de cannabis full spectrum como terapêutica complementar

    by Ana Beatriz Medeiros e Paula, Igor Bronzeado Cahino Moura de Almeida, Luíza Alcântara Pontes de Lemos, Katy Lísias Gondim Dias de Albuquerque

    Introdução: O Transtorno do Espectro Autista (TEA) caracteriza-se por déficits na comunicação e na interação social, além de comportamentos repetitivos e restritivos, geralmente manifestados por volta dos 3 anos. Objetivos: Avaliar a resposta terapêutica de cinco pacientes pediátricos com TEA que utilizaram óleo de cannabis full spectrum rico em canabidiol (CBD) 20 mg/ml associado ao tratamento medicamentoso convencional, acompanhados na Atenção Primária à Saúde no primeiro semestre de 2024. Métodos: Realizou-se um estudo observacional e descritivo, do tipo série de casos, baseado em busca ativa em prontuários digitais. Utilizaram-se instrumentos validados para diagnóstico e avaliação clínica (Childhood Autism Rating Scale - CARS e Autism Treatment Evaluation Checklist - ATEC), além de roteiro semiestruturado fundamentado na Case Report (CARE checklist), permitindo a coleta de dados essenciais sobre a evolução dos pacientes que faziam uso complementar do óleo de cannabis. Resultados: Dos cinco pacientes, três eram meninos e duas meninas, entre 5 e 11 anos. Dois foram classificados com autismo grave e três com autismo leve a moderado. A média de idade ao diagnóstico foi de 42,6 meses, e o uso de CBD durou, em média, 7,4 meses. Todos apresentaram melhora expressiva em sintomas como agressividade, insônia, hiperatividade, interação social, comportamentos repetitivos, seletividade alimentar e concentração. As medicações associadas incluíram risperidona, clorpromazina, lamotrigina e topiramato, sendo a risperidona a mais utilizada. Conclusão: O óleo de cannabis rico em CBD demonstrou efeitos terapêuticos positivos em pacientes com sintomas persistentes do TEA, sem registro de eventos adversos relacionados ao seu uso inicial.

  • Open Access

    Full Spectrum Cannabis Oil for the treatment of chronic pain and sleep dysfunction in myofascial temporomandibular disorder: a case report

    by L. V. Pinheiro, E. L. L. Prado, M. S. Januzzi, C. T. M. I. Issa, K. L. G. D. Albuquerque, J. L. O. Schiavon, E. G. Nunes, R. D. Castro, F. G. Pucci, O. J. A. Alves, et al.

    Medicinal cannabis has been the subject of extensive research, with recent studies demonstrating its potential in managing chronic pain and enhancing quality of life. This case report examines the use of medicinal cannabis in a patient treated at the School of Dentistry of Araçatuba (FOA-UNESP). The patient, a 28-year-old female with no comorbidities, presented with chronic muscular TMD and reported poor sleep quality. Full-spectrum cannabis oil (1:1 ratio of THC to CBD), was prescribed for a period of 60 days, with a maximum dosage of 10 drops per day. Pain intensity was measured using the Visual Analog Scale (VAS), while sleep quality was assessed using the Pittsburgh Sleep Quality Index (PSQI). Evaluations were conducted at three intervals: baseline, day 30, and day 60. To ensure patient safety, pre- and post-treatment blood tests were performed, and dosage adjustments were made every three days under the supervision of the study’s medical team. The results revealed significant improvements in pain management, with the patient’s orofacial pain score decreasing from 7 to 3 on the NRS. Additionally, sleep quality improved, as reflected by a lower PSQI score (global sleep quality at level 6 at the end), indicating more restorative sleep. Throughout the treatment period, the patient experienced mild side effects, including drowsiness and gastrointestinal discomfort, which were effectively managed through dosage modifications. In conclusion, full-spectrum cannabis oil shows promise as a therapeutic strategy for managing orofacial pain and improving sleep quality, providing significant relief in conditions where other interventions are ineffective or poorly tolerated. Further research is warranted to better understand the therapeutic mechanisms and potential side effects of medicinal cannabis in the management of chronic pain and related conditions.


  • Open Access

    Cannabis oil in treating Parkinson’s disease: improvement of motor and non-motor symptoms: a case report

    by C. T. M. I. Issa, R. D. Castro, K. L. G. D. Albuquerque

    Parkinson’s disease (PD) is characterized by progressive loss of dopaminergic neurons in the substantia nigra pars compacta, which leads to a reduction in the production of dopamine. Medication with levodopa becomes less effective as the disease progresses. Despite the excellent results observed in clinical practice with the medicinal use of Cannabis in the treatment of PD, the level of scientific evidence is still limited due to the small number of studies published in this field. We present the case of a 77-year-old man diagnosed 22 years ago with PD in an advanced stage, with significant bradykinesia, tremor, and rigidity along with the inability to maintain an upright position and walk, exacerbated by a femur fracture. He also had advanced dysphagia, resulting in a gastrostomy. Although lucid, he showed no interest in conversation and tended to become depressed and isolated. He used Prolopa® with no satisfactory therapeutic response. After starting treatment with Cannabis sativa oil, he is now able to walk around the house frequently and eat pasty food regularly without choking or broncho-aspiration episodes. There has also been a significant improvement in non-motor symptoms; he is more active, cheerful, communicative, and attentive to his surroundings. Further studies are needed to elucidate these results and the mechanisms of action of cannabinoids through which they exert possible neuroprotective and neuroreparative effects. These compelling results suggest that cannabis oil may offer a valuable and effective therapeutic option for individuals with Parkinson's disease.


  • Top Cited Papers
    Open Access

    Evaluation of the efficacy and safety of cannabidiol-rich cannabis extract in children with autism spectrum disorder: randomized, double-blind, and placebo-controlled clinical trial

    by Estácio Amaro da Silva Junior, Wandersonia Moreira Brito Medeiros, João Paulo Mendes dos Santos, João Marçal Medeiros de Sousa, Filipe Barbosa da Costa, Katiúscia Moreira Pontes, Thaís Cavalcanti Borges, Carlos Espínola Neto Segundo, Ana Hermínia Andrade e Silva, Eliane Lima Guerra Nunes, et al.

    Trends Psychiatry Psychother, vol.0, nAheadOfPrint, p.0-0, 2022